Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for UroGen Pharma (URGN) over the last 6 years, with Sep 2025 value amounting to $296.7 million.

  • UroGen Pharma's Total Non-Current Liabilities rose 8.57% to $296.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.7 million, marking a year-over-year increase of 8.57%. This contributed to the annual value of $290.7 million for FY2024, which is 20.97% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Total Non-Current Liabilities is $296.7 million, which was down 0.55% from $298.3 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Total Non-Current Liabilities ranged from a high of $298.3 million in Q2 2025 and a low of $18.2 million during Q1 2021.
  • For the 3-year period, UroGen Pharma's Total Non-Current Liabilities averaged around $260.5 million, with its median value being $248.3 million (2024).
  • Data for UroGen Pharma's Total Non-Current Liabilities shows a peak YoY skyrocketed of 888.39% (in 2022) over the last 5 years.
  • UroGen Pharma's Total Non-Current Liabilities (Quarterly) stood at $108.5 million in 2021, then skyrocketed by 104.59% to $222.0 million in 2022, then rose by 8.27% to $240.3 million in 2023, then grew by 20.97% to $290.7 million in 2024, then increased by 8.57% to $296.7 million in 2025.
  • Its last three reported values are $296.7 million in Q3 2025, $298.3 million for Q2 2025, and $290.3 million during Q1 2025.